Overview
- Furukawa, T. et al. (1999) J.P.E.T. 291, 464.
- Furukawa, T. et al. (2005) J. Cardiovasc. Pharmacol. 45, 241.
Alomone Labs Felodipine blocks L-type Ca2+ currents in Xenopus oocytes.Superimposed current traces of L-type channels (CaV1.2+α2δ1+β1a), before and during applications of 1 and 10 μM Felodipine (#F-105) as indicated on the left. Holding potential was -100 mV and currents were elicited every 10 seconds by 100 ms steps to +10 mV.
- Hockerman, G. H. et al. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 361.
- Haller, H. (2008) Int. J. Clin. Pract. 62, 781.
- Furukawa, T. et al. (1999) J.P.E.T. 291, 464.
- Furukawa, T. et al. (2005) J. Cardiovasc. Pharmacol. 45, 241.
- Hagiwara, S. et al. (1993) Euro. J. Pharmacol. 234, 1.
L-type (CaV1), voltage-gated Ca2+ channels are plasma membrane protein complexes which allow the passage of Ca2+ ions into cells following depolarization of the membrane potential. L-type channels are widely expressed in cardiac and smooth muscle in which they control contraction and therefore were recognized as a therapeutic target for cardiovascular diseases1,2.
Dihydropyridines (DHP) are molecules that act as allosteric modulators of L-type channels and many are used in the clinic to treat hypertension2. Felodipine is a DHP that acts as L-type, voltage-gated Ca2+ channel blocker and is used in the clinic to treat hypertension2. Felodipine is used as a pharmacological tool to specifically target L-type channels in expression systems3,4 as well as in physiological preparations5. The effective concentration of felodipine varies between systems for example; it is higher for inhibition of smooth muscle high K+ induced contraction than for inhibition of the intracellular Ca2+ elevation in these cells5.
Felodipine (#F-105) is a highly pure, synthetic, and biologically active compound.
Powered by Bioz